AFC-HD AMS Life Science Co., Ltd. provided consolidated earnings guidance for the fiscal year ending August 31, 2023. For the year, the company expects net sales of JPY 25,042 million, operating profit of JPY 1,555 million, profit attributable to owners of parent of JPY 983 million and basic earnings per share of JPY 70.36.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
862 JPY | +1.29% | +0.12% | +7.75% |
1st Jan change | Capi. | |
---|---|---|
+7.75% | 77.48M | |
+16.86% | 8.43B | |
+5.05% | 7.49B | |
+4.89% | 6.23B | |
-5.23% | 3.75B | |
-6.58% | 3.75B | |
-3.55% | 1.33B | |
-28.64% | 1.09B | |
+18.12% | 1.02B | |
-8.60% | 933M |
- Stock Market
- Equities
- 2927 Stock
- News AFC-HD AMS Life Science Co., Ltd.
- AFC-HD AMS Life Science Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending August 31, 2023